Walmart, Inc. (WMT) and Sam’s club pharmacies have said that they are ready to dispense the FDA authorized COVID-19 antiviral medications, Paxlovid and Molnupiravir, from this week. The medication will be available in certain stores in a limited number of states until more supply is available.
The companies said that the medicines will be given only after presenting a prescription from a healthcare provider. Moreover, the medicines will be available by curbside pickup or via drive-through pharmacy windows.
The companies seek to support the government in increasing the access and availability of authorized antiviral medication and vaccines.
Stock Rating
Last month, Credit Suisse analyst Robert Moskow maintained a Buy rating on Walmart with a price target of $166 (16.3% upside potential from current level).
Overall, the rest of the Street is bullish on the stock and has a Strong Buy consensus rating based on 14 Buys and 3 Holds. The average Walmart price target of $172.53 implies upside potential of about 20.9% from current levels.
Website Traffic
TipRanks’ Website Traffic tool, which uses data from SEMrush Holdings (SEMR), the world’s biggest website usage monitoring service, offers insight into Walmart’s performance.
According to the tool, in November, the Walmart website recorded a 7.4% monthly decrease in global unique visits, compared to the previous year. Whereas, year-to-date website traffic has grown 10.6% against the same period last year. Download the mobile app now, available on iOS and Android.
Related News:
Vista Acquires Stone Glacier; Street Says Buy
I-Mab to Start Phase 2 Trial of Enoblituzumab in China
Sutro and Tasly Enter Agreement to Develop STRO-002 in Greater China
